产品
编 号：F743469
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1243266-04-7
产品详情
生物活性：
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC).
体内研究：
Tovetumab (0.6-60 mg/kg, i.v.) blocks the PDGFRα-mediated elimination of PDGF-AA, leading to an increase in circulating PDGF-AA level in Cynomolgus monkeys.Tovetumab (10 mg/kg, i.p., twice a week) inhibits tumor growth in U118 glioma xenografts.Animal Model:Cynomolgus monkey
Dosage:0.6, 6.0, and 60 mg/kg
Administration:Intravenous injection (i.v.)
Result:Induced > 100- fold increases in circulating concentrations of PDGF-AA.
Animal Model:U118 glioma xenografts (CB17 SCID)
Dosage:10 mg/kg
Administration:Intraperitoneal injection (i.p.), twice per week.
Result:Produced 101% inhibition of tumor growth.
体外研究：
Tovetumab (10-100 nM, 1-2 h) binds to PDGFRα on H1703 cells (determined by Alexa647-labeled tovetumab). Tovetumab (0.001-10 nM, 10 min) inhibits ligand-induced phosphorylation of human PDGFRα in MG-63 cells.Tovetumab (0.001-100 nM, 72 h ) inhibits Ligand-induced proliferation of cancer-associated fibroblasts (CAFs) .
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC).
体内研究：
Tovetumab (0.6-60 mg/kg, i.v.) blocks the PDGFRα-mediated elimination of PDGF-AA, leading to an increase in circulating PDGF-AA level in Cynomolgus monkeys.Tovetumab (10 mg/kg, i.p., twice a week) inhibits tumor growth in U118 glioma xenografts.Animal Model:Cynomolgus monkey
Dosage:0.6, 6.0, and 60 mg/kg
Administration:Intravenous injection (i.v.)
Result:Induced > 100- fold increases in circulating concentrations of PDGF-AA.
Animal Model:U118 glioma xenografts (CB17 SCID)
Dosage:10 mg/kg
Administration:Intraperitoneal injection (i.p.), twice per week.
Result:Produced 101% inhibition of tumor growth.
体外研究：
Tovetumab (10-100 nM, 1-2 h) binds to PDGFRα on H1703 cells (determined by Alexa647-labeled tovetumab). Tovetumab (0.001-10 nM, 10 min) inhibits ligand-induced phosphorylation of human PDGFRα in MG-63 cells.Tovetumab (0.001-100 nM, 72 h ) inhibits Ligand-induced proliferation of cancer-associated fibroblasts (CAFs) .
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备